Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research

Launched by SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Sep 17, 2019

Keywords

ClinConnect Summary

The Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research trial is focused on improving the diagnosis and treatment of type 1 diabetes. This study aims to better understand how to manage this condition through a series of educational activities for patients and by conducting research across multiple centers. It’s an important step toward providing more effective care for those living with type 1 diabetes.

To be eligible for this trial, participants should have a confirmed diagnosis of type 1 diabetes and be able to give consent, either themselves or through a family member. They also need to own a smartphone and be comfortable using apps like WeChat. Unfortunately, individuals with certain other health conditions, such as mental disorders or autoimmune diseases that complicate diabetes, cannot participate. If you join this trial, you can expect to receive support and information to help manage your diabetes more effectively, while also contributing to valuable research that could help others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals diagnosed with Type 1 Diabetes according to the 1999 World Health Organization report
• • Written informed consent from the patient or family representative;
• • Individuals who own smartphone and are capable of using wechat or apps
• Exclusion Criteria:
• • Non-t1dm patients with autoimmune polyendocrine adenopathy syndrome (APS) are the first disease
• • With mental disorders
• • Have any other condition or disease that may hamper from compliance with the protocol or complication of the trial